Myriad Genetics, Inc.MYGNNASDAQ
Loading
Operating Income Growth AcceleratingAccelerating
Percentile Rank100
5Y CAGR+43.8%
Year-over-Year Change
Year-over-year operating income growth rate
5Y CAGR
+43.8%/yr
Long-term compound
Percentile
P100
Near historical high
vs 5Y Ago
6.2x
Strong expansion
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 615.02% |
| Q3 2025 | 92.92% |
| Q2 2025 | -1035.17% |
| Q1 2025 | 25.64% |
| Q4 2024 | -95.00% |
| Q3 2024 | 45.21% |
| Q2 2024 | -30.82% |
| Q1 2024 | 11.15% |
| Q4 2023 | 47.75% |
| Q3 2023 | 47.14% |
| Q2 2023 | -117.82% |
| Q1 2023 | -13.48% |
| Q4 2022 | -2.22% |
| Q3 2022 | -152.81% |
| Q2 2022 | -19.46% |
| Q1 2022 | 65.43% |
| Q4 2021 | 46.06% |
| Q3 2021 | -284.13% |
| Q2 2021 | 55.46% |
| Q1 2021 | 0.00% |
| Q4 2020 | 100.00% |
| Q3 2020 | 42.02% |
| Q2 2020 | 48.92% |
| Q1 2020 | -1419.32% |
| Q4 2019 | 57.89% |
| Q3 2019 | -273.21% |
| Q2 2019 | -194.92% |
| Q1 2019 | -3.28% |
| Q4 2018 | 408.33% |
| Q3 2018 | -92.45% |
| Q2 2018 | -6.47% |
| Q1 2018 | 286.36% |
| Q4 2017 | -94.97% |
| Q3 2017 | 411.11% |
| Q2 2017 | 32.56% |
| Q1 2017 | -2.27% |
| Q4 2016 | 112.90% |
| Q3 2016 | -82.63% |
| Q2 2016 | -16.20% |
| Q1 2016 | -5.75% |